COLL
COLLEGIUM PHARMACEUTICAL, INC
Next earnings Aug 5, 2026 · consensus $1.76 EPS, $205M rev
Last earnings +7.7% on 2026-05-07
$36.59
▲ +5.02%$36.59▲ +22.46%
over 1Y
L $29.57EODHDH $49.84
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.0%
1W+9.4%
1M+8.6%
3M+12.8%
YTD-19.6%
1Y+22.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Revenue grew 23.6% YoY; but high leverage (liabilities/equity 4.5x).
Revenue (FY2025) $781M · FY2025
The read
Fundamentals and price both look middling — no strong edge either way.
COLLEGIUM PHARMACEUTICAL, INC shows $781M in FY2025 revenue (+23.6% YoY), a 8.1% net margin, and 20.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $277M | $464M | $567M | $631M | $781M |
| Gross profit | $151M | $209M | $326M | $377M | $463M |
| Operating income | $17.6M | $33.3M | $167M | $170M | $180M |
| Net income | $71.5M | -$25.0M | $48.2M | $69.2M | $62.9M |
| Diluted EPS | $1.86 | -$0.74 | $1.29 | $1.86 | $1.73 |
| Net margin | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$945M
EV / EBITDA5.2
EV / Sales1.2
EV / FCF2.9
P / FCF3.5
PEG (trailing)—
Earnings yield5.4%
FCF yield28.2%
Quality & risk
ROIC (est.)44.9%
Free cash flow$328M
Total debt$14.2M
Net cash$217M
Altman Z-Score1.44 distress
Piotroski F-Score5/9
Capital returns
Buyback yield2.2%
Dividend yield (est.)—
Shareholder yield2.2%
Shares Δ YoY+0.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-082026-06-10open ↗S-8Filing2026-06-01open ↗S-8Filing2026-06-01open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗4Period ending 2026-05-142026-05-18open ↗144Filing2026-05-18open ↗
Frequently asked
- Is COLLEGIUM PHARMACEUTICAL, INC (COLL) a buy?
- COLL currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 23.6% YoY; but high leverage (liabilities/equity 4.5x).
- What is COLL's fair value?
- A Modified-Graham model based on COLL's SEC fundamentals estimates a fair value of about $33.16. It is an estimate from reported earnings, not a price target.
- Is COLL overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, COLL currently appears fairly valued relative to its SEC-grounded earnings power.
- What is COLLEGIUM PHARMACEUTICAL, INC's quality score?
- COLL scores 70.35294117647058/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001267565, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:18:10 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.